查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1762247

癫痫药物市场、规模、占有率、趋势、产业分析报告：依类型、给药途径、抗癫痫药物类型、通路、地区、2025-2034年市场预测

Epilepsy Drugs Market Size, Share, Trends, Industry Analysis Report: By Type, Route of Administration, Antiepileptic Drugs Type, Distribution Channel, and Region - Market Forecast, 2025-2034
出版日期: | 出版商: Polaris Market Research | 英文 115 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的一项新研究，全球癫痫药物市场预计到2034年将达到 194.5亿美元。本研究报告对当前市场动态提供了详细的见解，并对未来的市场成长进行了分析。

癫痫药物市场包括用于管理和控制癫痫患者的癫痫发作的药物，癫痫是一种以大脑活动异常为特征的神经系统疾病。这些药物也称为抗癫痫药物（AED），透过稳定大脑中的神经讯号来防止导致癫痫发作的过度电活动。市面上有许多不同类型的AED，根据其治疗的癫痫类型，可分为第一代、第二代和第三代，以及窄谱和广谱。这些药物有多种剂型，包括口服、静脉注射和肌肉注射，可根据患者需求和医疗状况灵活采用治疗方法。

癫痫药物市场的需求受到多种因素的推动，例如癫痫盛行率的上升、药物配方的进步以及对神经系统疾病的认识的提高。市场进行持续的研究和开发，以推出更安全、更有效、副作用更少的治疗方法。

此外，老年人口的成长、医疗支出的增加以及新兴地区医疗服务机会的改善也推动了市场扩张。监管部门的批准、新药的推出以及製药公司和研究机构之间的合作在塑造竞争格局方面发挥关键作用。随着治疗策略的发展，市场预计将受益于目的是最佳化癫痫发作控制和改善患者预后的创新药物开发和个人化医疗方法。

癫痫药物市场报告重点

根据类型，第三代抗癫痫药物将在2024年占据癫痫药物市场收入的最大占有率。这是因为与前几代药物相比，其安全性得到改善、疗效提高且副作用减少。

依给药途径划分，口服製剂占据了绝大多数市场占有率，因为它们是最常见和最方便的。包括片剂和缓释胶囊在内的多种口服剂型的出现提高了患者对治疗方案的依从性，推动了市场占有率的成长。

依抗癫痫药物类型划分，广谱抗癫痫药物（AED）呈现较高的成长率。广谱抗癫痫药可有效治疗多种癫痫类型，且比窄谱抗癫痫药物用途更广泛。对灵活、全面的治疗方案的需求不断成长，尤其是针对难治性癫痫的治疗方案，是推动该领域快速扩张的主要因素。

依地区划分，北美占据癫痫药物市场的最大占有率，这主要归功于先进的医疗保健基础设施、高度的认知度以及强大的研发计划。

癫痫药物市场有几家主要公司积极从事癫痫药物的开发和供应。主要公司包括UCB S.A.、Sanofi、Pfizer Inc.、Eisai Co., Ltd.、Abbott Laboratories、Novartis AG、GlaxoSmithKline plc、Sunovion Pharmaceuticals Inc.（Sumitomo Pharma的子公司）、Jazz Pharmaceuticals plc、Neurelis Inc.、Takeda Pharmaceutical Company、Sun Pharmaceutical Industries Limited。

目录

第1章 简介

第2章 执行摘要

第3章 研究方法

第4章 全球癫痫药物市场洞察

  • 市场概况
  • 癫痫药物市场动态
    • 驱动因素和机会
      • 癫痫盛行率不断上升
      • 抗癫痫药物研发的进展
    • 抑制因素和挑战
      • 相当一部分癫痫患者对药物有抗药性
  • PESTEL 分析
  • 癫痫药物市场的应用趋势
  • 价值链分析
  • COVID-19 影响分析

第5章 全球癫痫药物市场（依类型）

  • 主要调查结果
  • 简介
  • 第一代抗癫痫药物
  • 第二代抗癫痫药物
  • 第三代抗癫痫药物

第6章 全球癫痫药物市场（依给药途径）

  • 主要调查结果
  • 简介
  • 口服
  • 静脉注射
  • 肌肉注射

第7章 全球癫痫药物市场（依抗癫痫药物类型）

  • 主要调查结果
  • 简介
  • 窄谱AED
  • 广谱AED

第8章 全球癫痫药物市场（依地区）

  • 主要调查结果
  • 简介
    • 癫痫药物市场分析：地区，2020-2034
  • 北美
    • 北美：依类型，2020年至2034年
    • 北美：依给药途径，2020年至2034年
    • 北美：依抗癫痫药物类型，2020年至2034年
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲：依类型，2020年至2034年
    • 欧洲：依给药途径，2020年至2034年
    • 欧洲：依抗癫痫药物类型，2020年至2034年
    • 英国
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 荷兰
    • 俄罗斯
    • 其他欧洲国家
  • 亚太地区
    • 亚太地区：依类型，2020年至2034年
    • 亚太地区：依给药途径，2020年至2034年
    • 亚太地区：依抗癫痫药物类型，2020年至2034年
    • 中国
    • 印度
    • 马来西亚
    • 日本
    • 印尼
    • 韩国
    • 澳洲
    • 其他亚太地区
  • 中东和非洲
    • 中东及非洲：依类型，2020年至2034年
    • 中东和非洲：依给药途径，2020年至2034年
    • 中东和非洲：依抗癫痫药物类型，2020年至2034年
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 以色列
    • 南非
    • 其他中东和非洲地区
  • 拉丁美洲
    • 拉丁美洲：依类型，2020年至2034年
    • 拉丁美洲：依给药途径，2020年至2034年
    • 拉丁美洲：依抗癫痫药物类型，2020年至2034年
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他拉丁美洲国家

第9章 竞争格局

  • 扩张与收购分析
    • 扩张
    • 收购
  • 伙伴关係/协作/协议/公开

第10章 公司简介

  • Abbott Laboratories
  • Eisai Co., Ltd.
  • GlaxoSmithKline plc
  • Jazz Pharmaceuticals plc
  • Neurelis Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Limited
  • Sunovion Pharmaceuticals Inc.（a subsidiary of Sumitomo Pharma）
  • Takeda Pharmaceutical Company
  • UCB S.A.
Product Code: PM1315

The global epilepsy drugs market size is expected to reach USD 19.45 billion by 2034, according to a new study by Polaris Market Research. The report "Epilepsy Drugs Market Size, Share, Trends, Industry Analysis Report: By Type (First Generation Anti-epileptics, Second Generation Anti-epileptics, and Third Generation Anti-epileptics), Route of Administration, Antiepileptic Drugs Type, Distribution Channel, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The epilepsy drugs market comprises pharmaceutical products designed to manage and control seizures in individuals diagnosed with epilepsy, a neurological disorder characterized by abnormal brain activity. These drugs, also known as antiepileptic drugs (AEDs), function by stabilizing nerve signals in the brain to prevent excessive electrical activity that leads to seizures. The market includes various types of AEDs, categorized into first-generation, second-generation, and third-generation drugs, as well as narrow-spectrum and broad-spectrum AEDs, which differ based on their targeted seizure types. These medications are available in different formulations, including oral, intravenous, and intramuscular, allowing flexibility in treatment approaches based on patient needs and medical conditions.

The epilepsy drugs market demand is driven by several factors, including the rising prevalence of epilepsy, advancements in drug formulations, and increased awareness of neurological disorders. The market is witnessing continuous research and development efforts to introduce safer and more effective treatment options with minimal side effects.

Additionally, the growing elderly population, rising healthcare expenditures, and improved access to medical treatment in emerging regions are fueling market expansion. Regulatory approvals, new drug launches, and collaborations between pharmaceutical companies and research institutions play a crucial role in shaping the competitive landscape. As treatment strategies evolve, the market is expected to benefit from innovative drug development and personalized medicine approaches aimed at optimizing seizure control and improving patient outcomes.

Epilepsy Drugs Market Report Highlights

By type, The third generation anti-epileptics segment holds the largest share of the epilepsy drugs market revenue in 2024 due to their improved safety profiles, enhanced efficacy, and reduced side effects compared to earlier generations.

By route of administration, the oral segment dominates the epilepsy drugs market share as it is the most commonly used and convenient method for administering epilepsy drugs. The availability of a wide range of oral formulations, including tablets and extended-release capsules, enhances patient adherence to treatment regimens, driving its market share.

By antiepileptic drugs type, the broad-spectrum AEDs segment is experiencing a higher growth rate, as these drugs are effective in treating multiple types of seizures, making them more versatile than narrow-spectrum AEDs. The increasing demand for flexible and comprehensive treatment options, especially in cases of drug-resistant epilepsy, is a key factor contributing to this segment's rapid expansion.

By region, North America holds the largest share of the epilepsy drugs market, primarily due to its advanced healthcare infrastructure, high awareness levels, and robust research and development initiatives.

The epilepsy drugs market features several major companies actively involved in developing and providing treatments for epilepsy. A few key players include UCB S.A.; Sanofi; Pfizer Inc.; Eisai Co., Ltd.; Abbott Laboratories; Novartis AG; GlaxoSmithKline plc; Sunovion Pharmaceuticals Inc. (a subsidiary of Sumitomo Pharma); Jazz Pharmaceuticals plc; Neurelis Inc.; Takeda Pharmaceutical Company; and Sun Pharmaceutical Industries Limited.

Polaris Market Research has segmented the epilepsy drugs market report on the basis of type, route of administration, antiepileptic drugs type, distribution channel, and region:

By Type Outlook (Revenue-USD Billion, 2020-2034)

First Generation Anti-epileptics

Second Generation Anti-epileptics

Third Generation Anti-epileptics

By Route of Administration Outlook (Revenue-USD Billion, 2020-2034)

Oral

Intravenous

Intra-muscular

By Antiepileptic Drugs Type Outlook (Revenue-USD Billion, 2020-2034)

Narrow-Spectrum AEDs

Broad-Spectrum AEDs

By Distribution Channel Outlook (Revenue-USD Billion, 2020-2034)

Hospital Pharmacies

Retail Pharmacies

Others

By Regional Outlook (Revenue-USD Billion, 2020-2034)

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

Suth Korea

Indnesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

Suth Africa

Rest of Middle East & Africa

Latin America

Mexic

Brazil

Argentina

Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Source
    • 3.2.1. Primary Source
    • 3.2.2. Secondary Source

4. Global Epilepsy Drugs Market Insights

  • 4.1. Epilepsy Drugs Market - Market Snapshot
  • 4.2. Epilepsy Drugs Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing Prevalence of Epilepsy
      • 4.2.1.2. Advancements in Antiepileptic Drug Development
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Drug resistance in a significant percentage of epilepsy patients
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Epilepsy Drugs Market Application Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Epilepsy Drugs Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • 5.3. First Generation Anti-epileptics
    • 5.3.1. Global Epilepsy Drugs Market, by First Generation Anti-epileptics, by Region, 2020-2034 (USD Billion)
  • 5.4. Second Generation Anti-epileptics
    • 5.4.1. Global Epilepsy Drugs Market, by Second Generation Anti-epileptics, by Region, 2020-2034 (USD Billion)
  • 5.5. Third Generation Anti-epileptics
    • 5.5.1. Global Epilepsy Drugs Market, by Third Generation Anti-epileptics, by Region, 2020-2034 (USD Billion)

6. Global Epilepsy Drugs Market, by Route of Administration

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • 6.3. Oral
    • 6.3.1. Global Epilepsy Drugs Market, by Oral, by Region, 2020-2034 (USD Billion)
  • 6.4. Intravenous
    • 6.4.1. Global Epilepsy Drugs Market, by Intravenous, by Region, 2020-2034 (USD Billion)
  • 6.5. Intra-muscular
    • 6.5.1. Global Epilepsy Drugs Market, by Intra-muscular, by Region, 2020-2034 (USD Billion)

7. Global Epilepsy Drugs Market, by Antiepileptic Drugs Type

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 7.3. Narrow-Spectrum AEDs
    • 7.3.1. Global Epilepsy Drugs Market, by Narrow-Spectrum AEDs, by Region, 2020-2034 (USD Billion)
  • 7.4. Broad-Spectrum AEDs
    • 7.4.1. Global Epilepsy Drugs Market, by Broad-Spectrum AEDs, by Region, 2020-2034 (USD Billion)

8. Global Epilepsy Drugs Market, by Geography

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Epilepsy Drugs Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 8.3. Epilepsy Drugs Market - North America
    • 8.3.1. North America: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.3.2. North America: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.3.3. North America: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
    • 8.3.4. Epilepsy Drugs Market - U.S.
      • 8.3.4.1. U.S.: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
      • 8.3.4.2. U.S.: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 8.3.4.3. U.S.: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
    • 8.3.5. Epilepsy Drugs Market - Canada
      • 8.3.5.1. Canada: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
      • 8.3.5.2. Canada: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 8.3.5.3. Canada: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 8.4. Epilepsy Drugs Market - Europe
    • 8.4.1. Europe: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.4.2. Europe: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.4.3. Europe: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
    • 8.4.4. Epilepsy Drugs Market - UK
      • 8.4.4.1. UK: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
      • 8.4.4.2. UK: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 8.4.4.3. UK: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
    • 8.4.5. Epilepsy Drugs Market - France
      • 8.4.5.1. France: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
      • 8.4.5.2. France: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 8.4.5.3. France: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
    • 8.4.6. Epilepsy Drugs Market - Germany
      • 8.4.6.1. Germany: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
      • 8.4.6.2. Germany: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 8.4.6.3. Germany: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
    • 8.4.7. Epilepsy Drugs Market - Italy
      • 8.4.7.1. Italy: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
      • 8.4.7.2. Italy: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 8.4.7.3. Italy: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
    • 8.4.8. Epilepsy Drugs Market - Spain
      • 8.4.8.1. Spain: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
      • 8.4.8.2. Spain: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 8.4.8.3. Spain: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
    • 8.4.9. Epilepsy Drugs Market - Netherlands
      • 8.4.9.1. Netherlands: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
      • 8.4.9.2. Netherlands: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 8.4.9.3. Netherlands: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
    • 8.4.10. Epilepsy Drugs Market - Russia
      • 8.4.10.1. Russia: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
      • 8.4.10.2. Russia: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 8.4.10.3. Russia: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
    • 8.4.11. Epilepsy Drugs Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
      • 8.4.11.2. Rest of Europe: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 8.4.11.3. Rest of Europe: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 8.5. Epilepsy Drugs Market - Asia Pacific
    • 8.5.1. Asia Pacific: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.5.2. Asia Pacific: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.5.3. Asia Pacific: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
    • 8.5.4. Epilepsy Drugs Market - China
      • 8.5.4.1. China: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
      • 8.5.4.2. China: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 8.5.4.3. China: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
    • 8.5.5. Epilepsy Drugs Market - India
      • 8.5.5.1. India: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
      • 8.5.5.2. India: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 8.5.5.3. India: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
    • 8.5.6. Epilepsy Drugs Market - Malaysia
      • 8.5.6.1. Malaysia: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
      • 8.5.6.2. Malaysia: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 8.5.6.3. Malaysia: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
    • 8.5.7. Epilepsy Drugs Market - Japan
      • 8.5.7.1. Japan: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
      • 8.5.7.2. Japan: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 8.5.7.3. Japan: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
    • 8.5.8. Epilepsy Drugs Market - Indonesia
      • 8.5.8.1. Indonesia: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
      • 8.5.8.2. Indonesia: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 8.5.8.3. Indonesia: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
    • 8.5.9. Epilepsy Drugs Market - South Korea
      • 8.5.9.1. South Korea: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
      • 8.5.9.2. South Korea: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 8.5.9.3. South Korea: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
    • 8.5.10. Epilepsy Drugs Market - Australia
      • 8.5.10.1. Australia: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
      • 8.5.10.2. Australia: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 8.5.10.3. Australia: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
    • 8.5.11. Epilepsy Drugs Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
      • 8.5.11.2. Rest of Asia Pacific: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 8.5.11.3. Rest of Asia Pacific: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 8.6. Epilepsy Drugs Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.6.2. Middle East & Africa: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.6.3. Middle East & Africa: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
    • 8.6.4. Epilepsy Drugs Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
      • 8.6.4.2. Saudi Arabia: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
    • 8.6.5. Epilepsy Drugs Market - UAE
      • 8.6.5.1. UAE: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
      • 8.6.5.2. UAE: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 8.6.5.3. UAE: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
    • 8.6.6. Epilepsy Drugs Market - Israel
      • 8.6.6.1. Israel: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
      • 8.6.6.2. Israel: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 8.6.6.3. Israel: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
    • 8.6.7. Epilepsy Drugs Market - South Africa
      • 8.6.7.1. South Africa: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
      • 8.6.7.2. South Africa: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 8.6.7.3. South Africa: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
    • 8.6.8. Epilepsy Drugs Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
      • 8.6.8.2. Rest of Middle East & Africa: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 8.6.8.3. Rest of Middle East & Africa: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 8.7. Epilepsy Drugs Market - Latin America
    • 8.7.1. Latin America: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.7.2. Latin America: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.7.3. Latin America: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
    • 8.7.4. Epilepsy Drugs Market - Mexico
      • 8.7.4.1. Mexico: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
      • 8.7.4.2. Mexico: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 8.7.4.3. Mexico: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
    • 8.7.5. Epilepsy Drugs Market - Brazil
      • 8.7.5.1. Brazil: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
      • 8.7.5.2. Brazil: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 8.7.5.3. Brazil: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
    • 8.7.6. Epilepsy Drugs Market - Argentina
      • 8.7.6.1. Argentina: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
      • 8.7.6.2. Argentina: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 8.7.6.3. Argentina: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
    • 8.7.7. Epilepsy Drugs Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
      • 8.7.7.2. Rest of Latin America: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
      • 8.7.7.3. Rest of Latin America: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Abbott Laboratories
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Eisai Co., Ltd.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. GlaxoSmithKline plc
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Jazz Pharmaceuticals plc
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Neurelis Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Novartis AG
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Pfizer Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Sanofi
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Sun Pharmaceutical Industries Limited
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Sunovion Pharmaceuticals Inc. (a subsidiary of Sumitomo Pharma)
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Takeda Pharmaceutical Company
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
  • 10.12. UCB S.A.
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Benchmarking
    • 10.12.4. Recent Development

List of Tables:

  • Table 1 Global Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 2 Global Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 3 Global Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 4 North America: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 5 North America: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 6 North America: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 7 U.S.: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 8 U.S.: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 9 U.S.: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 10 Canada: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 11 Canada: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 12 Canada: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 13 Europe: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 14 Europe: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 15 Europe: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 16 UK: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 17 UK: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 18 UK: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 19 France: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 20 France: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 21 France: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 22 Germany: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 23 Germany: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 24 Germany: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 25 Italy: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 26 Italy: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 27 Italy: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 28 Spain: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 29 Spain: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 30 Spain: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 31 Netherlands: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 32 Netherlands: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 33 Netherlands: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 34 Russia: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 35 Russia: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 36 Russia: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 37 Rest of Europe: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 38 Rest of Europe: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 39 Rest of Europe: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 40 Asia Pacific: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 41 Asia Pacific: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 42 Asia Pacific: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 43 China: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 44 China: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 45 China: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 46 India: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 47 India: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 48 India: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 49 Malaysia: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 50 Malaysia: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 51 Malaysia: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 52 Japan: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 53 Japan: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 54 Japan: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 55 Indonesia: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 56 Indonesia: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 57 Indonesia: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 58 South Korea: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 59 South Korea: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 60 South Korea: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 61 Australia: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 62 Australia: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 63 Australia: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 64 Rest of Asia Pacific: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 65 Rest of Asia Pacific: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 66 Rest of Asia Pacific: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 67 Middle East & Africa: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 68 Middle East & Africa: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 69 Middle East & Africa: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 70 Saudi Arabia: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 71 Saudi Arabia: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 72 Saudi Arabia: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 73 UAE: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 74 UAE: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 75 UAE: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 76 Israel: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 77 Israel: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 78 Israel: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 79 South Africa: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 80 South Africa: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 81 South Africa: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 82 Rest of Middle East & Africa: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 83 Rest of Middle East & Africa: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 84 Rest of Middle East & Africa: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 85 Latin America: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 86 Latin America: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 87 Latin America: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 88 Mexico: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 89 Mexico: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 90 Mexico: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 91 Brazil: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 92 Brazil: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 93 Brazil: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 94 Argentina: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 95 Argentina: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 96 Argentina: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • Table 97 Rest of Latin America: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 98 Rest of Latin America: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 99 Rest of Latin America: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)

List of Figures:

  • Figure 1. Global Epilepsy Drugs Market, 2020-2034 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Type
  • Figure 7. Global Epilepsy Drugs Market, by Type, 2024 & 2034 (USD Billion)
  • Figure 8. Market by Route of Administration
  • Figure 9. Global Epilepsy Drugs Market, by Route of Administration, 2024 & 2034 (USD Billion)
  • Figure 10. Market by Antiepileptic Drugs Type
  • Figure 11. Global Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2024 & 2034 (USD Billion)